Clinical Trial: An Investigation of N-Acetylcysteine and Fenoldopam As Renal Protection Agents for Cardiac Surgery

This study is currently recruiting patients.

Sponsors and Collaborators: Pulmonary Critical Care Associates of Baltimore
Abbott Laboratories
Information provided by: Pulmonary Critical Care Associates of Baltimore


Patients with abnormal kidney function are at increased risk of complications following heart surgery, including worsening kidney function possibly requiring dialysis, a prolonged stay in the critical care unit and hospital, and the increased risk of death. Prior attempts at kidney protection for heart surgery patients have had mixed results. Two medicines, fenoldopam and N-acetylcysteine, have been shown to protect kidney function in other circumstances that cause kidney stress. The purpose of this study is to determine whether these medications will help to maintain the function of diseased kidneys during heart surgery.
Condition Intervention Phase
Kidney Failure, Acute
Kidney Failure, Chronic
Cardiac surgical procedures
 Drug: N-acetylcysteine
 Drug: fenoldopam
Phase II

MedlinePlus related topics:  Kidney Failure

Study Type: Interventional
Study Design: Prevention, Randomized, Double-Blind, Placebo Control, Factorial Assignment, Efficacy Study

Further Study Details: 
Primary Outcomes: Length of post-operative hospital stay; Length of post-operative critical care stay; Creatinine clearance post-operative days 3, 14, and nadir
Secondary Outcomes: Days to post-operative creatinine clearance nadir; Intraoperative and post-operative pressor use (pressor-hours); Hospital costs; Mortality
Expected Total Enrollment:  80

Study start: May 2002

This is a randomized, double-blinded, placebo-controlled trial to evaluate fenoldopam and N-acetylcysteine (NAC) individually, and together, as renal protective agents for patients with renal insufficiency undergoing heart surgery. Subjects have chronic renal insufficiency with creatinine clearance (CrCl) </= 40cc/min but not on pre-operative dialysis, and receive: NAC 600 mg by mouth (po) twice a day (bid) or placebo starting 24 hours pre-operative and continuing through the day of surgery; and/or fenoldopam 0.1 mcg/kg/min intravenous (IV) or saline placebo at anesthetic induction and continuing for 48 hours. Outcome data include: nadir, post-operative day 3 and post-operative day 14 CrCl, time to CrCl nadir, length of Intensive Care Unit (ICU) stay, length of post-operative hospital stay, hospital costs, mortality, and the need for hemodialysis. Intraoperative and post-operative pressor use is being monitored. The enrollment will include 80 patients (20 in each group).


Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Inclusion Criteria:

Exclusion Criteria:

  • Pre-operative ongoing dialysis
  • Nausea and vomiting
  • Uncontrolled glaucoma
  • Allergy to metabisulfite
  • Enrollment in another clinical study within 30 days
  • Pregnancy
  • Acute renal failure

Location and Contact Information

Please refer to this study by identifier  NCT00122018

Linda F Barr, MD      410-321-5651
Ellen Brahim      410-825-6456 

      St. Joseph Medical Center, Baltimore,  Maryland,  21204,  United States; Recruiting
Donna S Smith  410-427-2334 
Linda F Barr, MD,  Principal Investigator

Study chairs or principal investigators

Linda F Barr, MD,  Principal Investigator,  Pulmonary and Critical Care Assoc. of Baltimore   

More Information

Study ID Numbers:  REPORT
Record last reviewed:  February 2005
Last Updated:  July 25, 2005
Record first received:  July 21, 2005 Identifier:  NCT00122018
Health Authority: United States: Institutional Review Board processed this record on 2005-07-26


Common Treatments

[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Follow Us